MEDIPOST CDMO service
MEDIPOST follows a strong quality policy that adheres to the latest GMP regulations and provide the best CDMO service to our clients based on our extensive experience in product approval obtainment and due diligence.
in Stem Cell Therapeutics
Number of registered patents in Korea and overseas
Number of national R&D grants received in Korea
Number of private cord blood units stored
Percentage of R&D staff
1st Generation Cord Blood-derived Stem Cell Products
PNEUMOSTEM® an allogeneic umbilical cord blood-derived mesenchymal stem cell product, is currently under development for the preventive treatment of Bronchopulmonary Dysplasia(BPD) in premature infants. Currently, Phase 2 clinical trial is ongoing in Korea and PNEUMOSTEM® has been Orphan Drug designated by US FDA and EMA. Recently, US FDA granted a Fast Track Designation for PNEUMOSTEM®.
2nd Generation Cord Blood-derived Stem Cell Products